C. Dujon

1.3k total citations
22 papers, 382 citations indexed

About

C. Dujon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, C. Dujon has authored 22 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Surgery. Recurrent topics in C. Dujon's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). C. Dujon is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Colorectal Cancer Treatments and Studies (5 papers). C. Dujon collaborates with scholars based in France, French Polynesia and Réunion. C. Dujon's co-authors include C. Chouaïd, A. Vergnenègre, H. Bérard, H. Le Caer, G. Robinet, P. Thomas, Chrystèle Locher, R. Corre, J.B. Auliac and J. Le Treut and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C. Dujon

20 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Dujon France	11	323	215	115	63	31	22	382
Fernando Barata Portugal	11	294 0.9×	262 1.2×	54 0.5×	72 1.1×	25 0.8×	61	438
Yves Rinaldi France	11	132 0.4×	343 1.6×	98 0.9×	39 0.6×	63 2.0×	47	410
Jacky Créquit France	9	306 0.9×	229 1.1×	29 0.3×	39 0.6×	47 1.5×	18	368
Guillaume Beinse France	12	93 0.3×	125 0.6×	160 1.4×	138 2.2×	41 1.3×	33	361
Élizabeth Fabre-Guillevin France	8	121 0.4×	106 0.5×	37 0.3×	52 0.8×	21 0.7×	18	264
Henrique Queiroga Portugal	11	170 0.5×	122 0.6×	45 0.4×	28 0.4×	25 0.8×	37	253
M. Guirado Spain	9	254 0.8×	202 0.9×	37 0.3×	54 0.9×	27 0.9×	24	361
Jeffrey T. Yorio United States	8	136 0.4×	193 0.9×	50 0.4×	30 0.5×	70 2.3×	22	323
Francesco Cortiula Italy	10	170 0.5×	202 0.9×	48 0.4×	51 0.8×	35 1.1×	38	324
Jeffrey M. Crane United States	7	280 0.9×	153 0.7×	91 0.8×	146 2.3×	35 1.1×	10	357

Countries citing papers authored by C. Dujon

Since Specialization

Citations

This map shows the geographic impact of C. Dujon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Dujon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Dujon more than expected).

Fields of papers citing papers by C. Dujon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Dujon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Dujon. The network helps show where C. Dujon may publish in the future.

Co-authorship network of co-authors of C. Dujon

This figure shows the co-authorship network connecting the top 25 collaborators of C. Dujon. A scholar is included among the top collaborators of C. Dujon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Dujon. C. Dujon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Molinier, O., J. Pinsolle, Sebastian Schneider, et al.. (2024). COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study. Respiratory Medicine and Research. 86. 101093–101093. 1 indexed citations

Molinier, O., I. Monnet, C. Decroisette, et al.. (2022). 509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study. Annals of Oncology. 33. S775–S776. 1 indexed citations

Kamga, Paul Takam, Adrien Costantini, Catherine Julié, et al.. (2022). Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. Cancer Immunology Immunotherapy. 71(11). 2791–2799. 4 indexed citations

Girard, Nicolas, Vincent Fallet, V. Gounant, et al.. (2022). Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study. Targeted Oncology. 17(6). 675–682. 12 indexed citations

Debieuvre, D., Chrystèle Locher, Bernard Asselain, et al.. (2019). Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies. Bulletin du Cancer. 106(4). 283–292. 15 indexed citations

Cadranel, Jacques, Roger Lacave, Anaïs Pujals, et al.. (2019). Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. Lung Cancer. 137. 149–156. 65 indexed citations

Caer, H. Le, Isabelle Borget, R. Corre, et al.. (2017). Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. Journal of Thoracic Disease. 9(10). 3747–3754. 13 indexed citations

Lerouge, D., Alain Rivière, Éric Dansin, et al.. (2014). A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 14(1). 231–231. 16 indexed citations

Chouaïd, C., C. Dujon, Pascal Dô, et al.. (2014). Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 86(2). 170–173. 132 indexed citations

10.

Chouaïd, C., H. Le Caer, R. Corre, et al.. (2012). Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505). Clinical Lung Cancer. 14(2). 103–107. 12 indexed citations

11.

Greillier, Laurent, R. Corre, Jacky Créquit, et al.. (2012). A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer. 77(1). 97–103. 18 indexed citations

12.

Borget, Isabelle, M. Pérol, David Pérol, et al.. (2012). Cost-utility analysis of maintenance therapy with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502-eco phase III study.. Journal of Clinical Oncology. 30(15_suppl). e16560–e16560.

13.

Barlési, Fabrice, R. Corre, Suzanna Bota, et al.. (2011). A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). British Journal of Cancer. 105(8). 1123–1130. 20 indexed citations

14.

Vergnenègre, A., R. Corre, H. Bérard, et al.. (2010). Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. Journal of Thoracic Oncology. 6(1). 161–168. 27 indexed citations

15.

Caer, H. Le, Fabrice Barlési, Suzanna Bota, et al.. (2010). A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504.. Journal of Clinical Oncology. 28(15_suppl). 7536–7536. 1 indexed citations

16.

Dujon, C., R. Azarian, & P Petitpretz. (2009). Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d’une série rétrospective. Revue des Maladies Respiratoires. 26(9). 952–960. 7 indexed citations

17.

Piquet, J., J.-M. Chavaillon, P. David, et al.. (2009). Caractéristiques et prise en charge des exacerbations aiguës de BPCO hospitalisées. Étude EABPCO–CPHG du Collège des pneumologues des hôpitaux généraux. Revue des Maladies Respiratoires. 27(1). 19–29. 10 indexed citations

18.

Vergnenègre, A., H. Bérard, D. Paillotin, et al.. (2009). PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY. Value in Health. 12(7). A281–A281. 1 indexed citations

19.

Dujon, C., R. Azarian, F Mignon, & P Petitpretz. (2006). Retour veineux pulmonaire anormal révélé par un œdème pulmonaire localisé. Revue des Maladies Respiratoires. 23(1). 89–91.

20.

Dujon, C., et al.. (2006). Cancer bronchique du sujet âgé : Performance Status et/ou indices gériatriques ?. Revue des Maladies Respiratoires. 23(4). 307–318. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact